Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clarithromycin + rifampicin + ethambutol
- Development stage
- Phase 4
- Lead developer
- Taisho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A three-drug antibiotic regimen consisting of clarithromycin, rifampicin, and ethambutol, primarily used for the treatment of Mycobacterium avium complex (MAC) infections. This combination is recommended by the American Thoracic Society and the Infectious Diseases Society of America as a standard treatment approach for MAC pulmonary disease and other MAC infections. The regimen works through multiple mechanisms to combat mycobacterial infections and is typically administered for extended periods.
- Other names
- REC
02
Targets
Bacterial 50S ribosomal subunitrpoB (DNA-directed RNA polymerase subunit beta)AftA (Arabinosyltransferase AftA)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on clarithromycin + rifampicin + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clarithromycin + rifampicin + ethambutol.